Emerging data indicates that retatrutide, a dual-action medication, could represent a major advance in weight management. This treatment combines the effects of a GLP-1 analog and a GIP agonist , potentially offering a greater impact than current therapies . Study assessments have revealed promising results , including significant reductions in we